glp-1 medication risks compounding pharmacies GI Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists FDA Intensifies Crackdown on GLP-1

GLP-1 Receptor Agonists Reduce Colorectal Cancer Risk in IBD Populations Cancer Network Staff Tim Cortese , Russ Conroy Retrospective data showed that GLP-1 receptor agonist use was associated with a 51% reduction in colorectal cancer odds among patients with inflammatory bowel disease

The authors emphasized that Ex4 did not impair general activity or induce aversive effects, further validating the specificity of its action on nicotine reinforcement mechanisms [40]

State Medicaid programs and manufacturers were requested to submit their intentions to participate by January 8, 2026, and the model is expected to begin in May 2026

Ozempic is first GLP-1 drug FDA-approved for kidney disease Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of worsening kidney disease in people with type 2 diabetes

Diabetes Care 37, 21492158

Several GLP-1 agonists have FDA approval for other indications that may overlap with BED patient populations: Semaglutide (Wegovy) and liraglutide (Saxenda) are approved for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity Semaglutide (Ozempic), liraglutide (Victoza), dulaglutide (Trulicity), and tirzepatide (Mounjaro) are approved for type 2 diabetes management Tirzepatide (Zepbound) is approved for chronic weight management When clinicians prescribe GLP-1 agonists for BED, this constitutes off-label use a legal and common practice in medicine when evidence suggests potential benefit and approved treatments are inadequate